The CytRx ENABLE Phase II clinical trial has demonstrated positive results for bafetinib, a Bcr-Abl, Lyn and Fyn kinase inhibitor for the treatment relapsed or refractory B-cell chronic lymphocytic leukaemia (B-CLL).
The trial involves 18 patients who self-administer bafetinib twice daily, and continue treatment as long as their cancer is controlled and no intolerable side effects occur.
Go deeper with GlobalData
The preliminary results from the study demonstrated that bafetinib was clinically active in a group of patients with B-CLL who have failed several other treatments for their cancer.
CytRx president and CEO Steven Kriegsman said the study allows them to assess preliminary efficacy and safety results following trial initiation before potentially moving into larger clinical trials.
"Earlier this year we reported favourable preliminary results from the ENABLE trial, and believe that our drug candidate’s unique kinase inhibitor formulation could be efficacious in treating B-CLL and other cancers where approved therapies have failed," Kriegsman added.
See Also:
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
